Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 3Enrolling by invitation 1

Sponsor Class

INDUSTRY 11OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3

Conditions

Neurofibromatosis 1 3

Interventions

Cyclophosphamide 956Radiotherapy 847Cisplatin 757Gemcitabine 657Carboplatin 603Docetaxel 598Paclitaxel 585Bevacizumab 580Fluorouracil 504Oxaliplatin 458Rituximab 453Surveys and Questionnaires 449Capecitabine 440Dexamethasone 428Doxorubicin 424Etoposide 411Irinotecan 389Cytarabine 376Filgrastim 369pembrolizumab 328Leucovorin 305Nivolumab 296fludarabine phosphate 294Melphalan 288Magnetic Resonance Spectroscopy 280Peripheral Blood Stem Cell Transplantation 279Blood Specimen Collection 279Methotrexate 276Lenalidomide 276Cetuximab 270

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × OTHER × Deoxycholic Acid × Clear all
NCT06132165 2025-11-21

Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous Neurofibromas

Massachusetts General Hospital

Phase 1 Completed
13 enrolled
CNS

Neurofibromatosis 1

NCT04730583 2025-02-21

Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas

Massachusetts General Hospital

Phase 1 Completed
34 enrolled
CNS

Neurofibromatosis 1

NCT06120036 2025-02-21

Dosing and Tolerability of Deoxycholic Acid vs. Polidocanol in the Treatment of Neurofibromatosis Type 1 Cutaneous Neurofibromas

Massachusetts General Hospital

Phase 1 Completed
20 enrolled
CNS

Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡